Citius Oncology (NASDAQ:CTOR - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.08) earnings per share for the quarter, Zacks reports.
Citius Oncology Trading Down 1.7%
Shares of NASDAQ:CTOR traded down $0.03 during trading on Tuesday, reaching $1.69. 133,639 shares of the company traded hands, compared to its average volume of 2,458,339. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.05 and a current ratio of 0.36. Citius Oncology has a 52 week low of $0.55 and a 52 week high of $6.19. The company's 50 day moving average is $2.39 and its two-hundred day moving average is $1.42.
Wall Street Analysts Forecast Growth
A number of research firms recently weighed in on CTOR. Wall Street Zen upgraded shares of Citius Oncology to a "hold" rating in a research note on Saturday, July 26th. Maxim Group downgraded shares of Citius Oncology from a "strong-buy" rating to a "hold" rating in a report on Friday, May 23rd. Finally, Citigroup cut shares of Citius Oncology to a "hold" rating in a research note on Friday, May 23rd.
Get Our Latest Stock Report on CTOR
Institutional Trading of Citius Oncology
An institutional investor recently raised its position in Citius Oncology stock. Geode Capital Management LLC grew its position in shares of Citius Oncology, Inc. (NASDAQ:CTOR - Free Report) by 179.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,297 shares of the company's stock after buying an additional 36,758 shares during the quarter. Geode Capital Management LLC owned 0.07% of Citius Oncology worth $249,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 70.52% of the company's stock.
About Citius Oncology
(
Get Free Report)
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Citius Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Citius Oncology wasn't on the list.
While Citius Oncology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access